In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding sharehol ...

The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), ...